Smilow Cancer Hospital

Recent papers from Smilow Cancer Hospital

1. Bispecific T-cell engagers beyond hematology: Expanding uses in solid tumorsJournal of Oncology Pharmacy Practice · 2026
2. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet · 2018
3. Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology · 2026
4. Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS/MS and immunoassays for estradiolThe Breast · 2026
5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet · 2016
6. Baseline cellular state shapes the molecular impact of mutant KRAS alleles in reconstituted pancreatic cancer cellsMolecular Omics · 2026
7. Anatomical location defines distinct molecular subtypes of mucosal melanomaESMO Open · 2026
8. Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A PodcastTargeted Oncology · 2026
9. Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systemsJournal of Neuro-Oncology · 2026
10. Blood Transfusion in End-of-Life Cancer Care: Clinical Evidence, Patient Blood Management and Goal-Concordant PracticeMedical Sciences · 2026
11. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologyJournal of the National Comprehensive Cancer Network · 2026
12. Reporting of atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting SystemAmerican Journal of Health-System Pharmacy · 2026
13. Advances in Cancer Immunotherapy for Solid TumorsAdvanced Science · 2026
14. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyJournal of Clinical Oncology · 2026
15. Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype ( KRASwt) non-small cell lung cancer (NSCLC).Journal of Clinical Oncology · 2026
16. Comparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis.Journal of Clinical Oncology · 2026
17. A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 ⁺ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.Journal of Clinical Oncology · 2026
18. Outcomes of infectious workup and antibiotic use during tarlatamab initiation in patients with advanced neuroendocrine carcinomas.Journal of Clinical Oncology · 2026
19. PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME).Journal of Clinical Oncology · 2026
20. CDH6-high gastric cancers as exhibitors of a reproducible vascular–stromal, immune-excluded tumor microenvironment.Journal of Clinical Oncology · 2026